CN101891786B - 一种利巴韦林化合物及其制法 - Google Patents
一种利巴韦林化合物及其制法 Download PDFInfo
- Publication number
- CN101891786B CN101891786B CN2010102439710A CN201010243971A CN101891786B CN 101891786 B CN101891786 B CN 101891786B CN 2010102439710 A CN2010102439710 A CN 2010102439710A CN 201010243971 A CN201010243971 A CN 201010243971A CN 101891786 B CN101891786 B CN 101891786B
- Authority
- CN
- China
- Prior art keywords
- triazole
- ribavirin
- solvent
- ribofuranosyl
- ethanoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 Ribavirin compound Chemical class 0.000 title claims abstract description 27
- 229960000329 ribavirin Drugs 0.000 title claims abstract description 27
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 21
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims abstract description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 14
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 12
- 229910021529 ammonia Inorganic materials 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 235000019441 ethanol Nutrition 0.000 claims description 6
- QMPFMODFBNEYJH-UHFFFAOYSA-N methyl 1h-1,2,4-triazole-5-carboxylate Chemical compound COC(=O)C1=NC=NN1 QMPFMODFBNEYJH-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 2
- 229960004217 benzyl alcohol Drugs 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 238000005915 ammonolysis reaction Methods 0.000 abstract description 3
- 238000006482 condensation reaction Methods 0.000 abstract description 3
- 230000035484 reaction time Effects 0.000 abstract description 3
- IHNHAHWGVLXCCI-FDYHWXHSSA-N [(2r,3r,4r,5s)-3,4,5-triacetyloxyoxolan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O IHNHAHWGVLXCCI-FDYHWXHSSA-N 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 6
- 229930010555 Inosine Natural products 0.000 description 5
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 5
- 229960003786 inosine Drugs 0.000 description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- ZEWJFUNFEABPGL-UHFFFAOYSA-N 1,2,4-triazole-3-carboxamide Chemical class NC(=O)C=1N=CNN=1 ZEWJFUNFEABPGL-UHFFFAOYSA-N 0.000 description 1
- RZMGZEJEAAVXRG-UHFFFAOYSA-N 1,2-dihydrotriazole-3-carboxylic acid Chemical compound N1NN(C=C1)C(=O)O RZMGZEJEAAVXRG-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OQRXBXNATIHDQO-UHFFFAOYSA-N 6-chloropyridine-3,4-diamine Chemical compound NC1=CN=C(Cl)C=C1N OQRXBXNATIHDQO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UBORTCNDUKBEOP-UHFFFAOYSA-N L-xanthosine Natural products OC1C(O)C(CO)OC1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UHFFFAOYSA-N 0.000 description 1
- 102100036286 Purine nucleoside phosphorylase Human genes 0.000 description 1
- 206010047482 Viral upper respiratory tract infection Diseases 0.000 description 1
- UBORTCNDUKBEOP-HAVMAKPUSA-N Xanthosine Natural products O[C@@H]1[C@H](O)[C@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-HAVMAKPUSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 108010009099 nucleoside phosphorylase Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- UBORTCNDUKBEOP-UUOKFMHZSA-N xanthosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UUOKFMHZSA-N 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102439710A CN101891786B (zh) | 2010-08-04 | 2010-08-04 | 一种利巴韦林化合物及其制法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102439710A CN101891786B (zh) | 2010-08-04 | 2010-08-04 | 一种利巴韦林化合物及其制法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101891786A CN101891786A (zh) | 2010-11-24 |
CN101891786B true CN101891786B (zh) | 2012-09-05 |
Family
ID=43101157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102439710A Expired - Fee Related CN101891786B (zh) | 2010-08-04 | 2010-08-04 | 一种利巴韦林化合物及其制法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101891786B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102127134B (zh) * | 2010-12-02 | 2012-11-14 | 海南美兰史克制药有限公司 | 一种利巴韦林化合物及其方法 |
CN102786571B (zh) * | 2011-05-17 | 2017-02-22 | 中国医学科学院药物研究所 | 利巴韦林晶d型及制备方法与在药品和保健品中应用 |
CN102786572A (zh) * | 2011-05-17 | 2012-11-21 | 中国医学科学院药物研究所 | 利巴韦林晶c型表征及制备方法与在药品和保健品中应用 |
CN102952104A (zh) * | 2011-08-17 | 2013-03-06 | 黑龙江省松花江药业有限公司 | 一种呋喃类化合物 |
CN104910215B (zh) * | 2015-05-22 | 2018-02-13 | 浙江工业大学 | 一种利用核苷裂解后四乙酰核糖结晶残液的方法 |
CN105693793B (zh) * | 2016-03-22 | 2018-12-21 | 湖北美林药业有限公司 | 一种利巴韦林化合物及其药物组合物 |
CN109134565A (zh) * | 2017-08-15 | 2019-01-04 | 李双喜 | 一种1/10水利巴韦林化合物及其药物组合物 |
CN109134566A (zh) * | 2017-08-18 | 2019-01-04 | 樊艳芳 | 一种1/20水利巴韦林化合物 |
CN111647033A (zh) * | 2020-06-08 | 2020-09-11 | 济南明鑫制药股份有限公司 | 一锅法制备利巴韦林的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1535278A (zh) * | 2001-07-30 | 2004-10-06 | �����ﰲ�ط���������ѧ(�����)�ɷ��� | 制备利巴韦林的方法 |
CN101397316A (zh) * | 2008-10-23 | 2009-04-01 | 浙江工业大学 | 一种利巴韦林缩合物的化学合成方法 |
-
2010
- 2010-08-04 CN CN2010102439710A patent/CN101891786B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1535278A (zh) * | 2001-07-30 | 2004-10-06 | �����ﰲ�ط���������ѧ(�����)�ɷ��� | 制备利巴韦林的方法 |
CN101397316A (zh) * | 2008-10-23 | 2009-04-01 | 浙江工业大学 | 一种利巴韦林缩合物的化学合成方法 |
Non-Patent Citations (2)
Title |
---|
J. T. Witkowski, et al..Design, Synthesis, and Broad Spectrum Antiviral Activity of 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide and Related Nucleosides.《Journal of Medicinal Chemsitry》.ACS,1972,第15卷(第11期),第1150-1154页. * |
J.T.Witkowski et al..Design |
Also Published As
Publication number | Publication date |
---|---|
CN101891786A (zh) | 2010-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101891786B (zh) | 一种利巴韦林化合物及其制法 | |
US5075445A (en) | Guanine derivatives | |
CN109575028B (zh) | 一种利用阳离子交换树脂催化-分离耦合技术水解腺嘌呤核苷的方法 | |
CN111253448A (zh) | 一种β-烟酰胺单核苷酸的制备方法和纯化方法 | |
US3300478A (en) | Arabinofuranosyl 2', 5'-and 3'-5'-dinucleoside phosphates and process therefor | |
CN102887892A (zh) | 4-叔丁基-2-(2-氟苯氨基)-5-(1,2,4-***-1-基)噻唑晶体 | |
CN102180914A (zh) | 一种2-脱氧-d-葡萄糖的制备方法 | |
CN101962367A (zh) | 一种盐酸苯达莫司汀的提纯方法 | |
CN101948492A (zh) | 化学合成法生产阿糖胞苷的工艺 | |
CN102344412A (zh) | 一种对氨基水杨酸异烟肼的制备方法 | |
CN111808018B (zh) | 一种啶虫脒的生产工艺 | |
CN101362787A (zh) | 替比夫定的制备方法 | |
CN104592334A (zh) | 5-羟甲基和5-醛基-2’-脱氧胞苷三磷酸四钠盐的合成方法 | |
CN101717420B (zh) | 一种合成尿嘧啶核苷的方法 | |
CN106866763A (zh) | 一种单磷酸阿糖腺苷的合成工艺 | |
CN109134569B (zh) | 一种单磷酸阿糖腺苷的生产工艺 | |
CN102532227A (zh) | 一种4-(2,4,6-三甲基苯氧基)-5-氟尿嘧啶衍生物的合成方法 | |
CN107602648B (zh) | 一种5’-腺苷酸的制备方法 | |
CN109517019B (zh) | 一种3β-乙酰氧基雄甾-5-烯-17-酮加成反应副产物的再利用方法 | |
CN103923143A (zh) | 一种合成双核苷四磷酸以及p2,p3-(双卤代)亚甲基双核苷四磷酸的方法 | |
CN105198864B (zh) | 一种环戊基嘧啶化合物的无溶剂制备方法 | |
CN113735917B (zh) | 一种氨基甲酰基胍核苷的制备方法 | |
CN114057813B (zh) | 一种合成胞二磷胆碱钠的方法 | |
CN107722090A (zh) | 制备利巴韦林的方法 | |
CN102050857B (zh) | 一种5-甲基尿苷的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN LINGKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG MING Effective date: 20130726 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570125 HAIKOU, HAINAN PROVINCE TO: 570216 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130726 Address after: 570216 Hainan Province, Haikou city Jinpan Industrial Development Zone Industrial Village No. 3-6 building Patentee after: Hainan Lingkang Pharmaceutical Co., Ltd. Address before: The new business building No. 48 570125 Hainan city of Haikou province China World Trade Center Road, room 2601 Patentee before: Wang Ming |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120905 Termination date: 20160804 |
|
CF01 | Termination of patent right due to non-payment of annual fee |